ANZ takes $22m stake in Pacific Edge

Fri, 24 Jul 2020

ANZ New Zealand Investments has bought $22 million of new shares in cancer diagnostics company Pacific Edge at a premium. Pacific Edge will issue 33.8 million shares to ANZ at 65 cents per share, a 14 percent premium to the volume weighted average share price over the previous 5-day trading period. The company currently has more than 689 million shares on issue. The share price jumped 17.24 percent to 68 cents in early trading, up 467 percent year-to-date. The investment from ANZ follows Pacific Edge’s breakthrough in the United State...

Subscribe to BusinessDesk

Stay informed on business, government and financial developments across New Zealand.

Deeply researched, twice-edited and fact-checked news
Annual subscribers also receive a complimentary subscription to The Wall Street Journal
Personalised email news alerts, plus gift up to 5 stories a month to non-subscribers

You can cancel anytime with two clicks, an email or a phone call.
Find out more.

We are serious about journalism.